NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AARD

Aardvark Therapeutics Inc

May 09 • 04:00PM ET

10.42

Dollar change -0.31
Percentage change -2.89	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF VTI VTWO VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	42.89%	Shs Outstand	21.70M	Perf Week	-18.97%
Market Cap	226.11M	Forward P/E	-	EPS next Y	-2.56	Insider Trans	18.67%	Shs Float	12.39M	Perf Month	33.76%
Income	-	PEG	-	EPS next Q	-0.67	Inst Own	10.99%	Short Float	2.58%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	48.98%	Inst Trans	8.32%	Short Ratio	2.14	Perf Half Y	-
Book/sh	-2.52	P/B	-	EPS next Y	2.38%	ROA	-	Short Interest	0.32M	Perf Year	-
Cash/sh	3.39	P/C	3.07	EPS next 5Y	17.23%	ROE	-	52W Range	4.88 - 19.58	Perf YTD	-27.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-46.78%	Beta	-
Dividend TTM	-	Quick Ratio	15.05	Sales past 5Y	0.00%	Gross Margin	-	52W Low	113.52%	ATR (14)	1.45
Dividend Ex-Date	-	Current Ratio	15.05	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	53.83	Volatility	16.03% 13.58%
Employees	22	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	31.50
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	1.44	Prev Close	10.73
Sales Surprise	-	EPS Surprise	39.02%	Sales Q/Q	-	Earnings	Mar 31 AMC	Avg Volume	149.46K	Price	10.42
SMA20	11.84%	SMA50	10.87%	SMA200	2.46%	Trades		Volume	215,243	Change	-2.89%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-25	Initiated	RBC Capital Mkts	Outperform	$21
Mar-10-25	Initiated	Morgan Stanley	Overweight	$29
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight	$50
Mar-10-25	Initiated	BofA Securities	Buy	$22

May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
02:55PM	Loading…
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Decheng Capital Global Life Sc	10% Owner	Feb 14 '25	Buy	16.00	1,250,000	20,000,000	2,958,887	Feb 19 05:44 PM
Lee Tien-Li	Chief Executive Officer	Feb 14 '25	Buy	16.00	16,542	264,672	1,496,175	Feb 19 04:35 PM
Sun Nelson	Chief Financial Officer	Feb 14 '25	Buy	16.00	10,000	160,000	99,484	Feb 19 04:30 PM
Cormorant Asset Management, LP	Former 10% Owner	Feb 14 '25	Buy	16.00	187,500	3,000,000	987,689	Feb 19 04:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AARD

Aardvark Therapeutics Inc

Upgrade your FINVIZ experience